Article
ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype.
Carcinogenesis - 1 Mar 2012
Smith A M, Findlay V J, Bandurraga S G, Kistner-Griffin E, Spruill L S, Liu A, Golshayan A R, Turner D P
Abstract excerpt
Advanced disease accounts for the majority of prostate cancer-related deaths and androgen deprivation therapy (ADT) is the standard of care for these patients. Many patients undergoing ADT become resistant to its effects and progress to castrate-resistant prostate cancer (CRPC). Current therapies for CRPC patients are inadequate, with progression-free survival rates as low as 2 months. The molecular events that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.